US 11,712,414 B2
Oral pharmaceutical composition for preventing or treating dry eye syndrome comprising rebamipide or a prodrug thereof
Eui Hwan Cho, Seoul (KR); Sung Ju Choi, Seoul (KR); Sung Woo Lee, Seoul (KR); Hee Jong Shin, Bucheon-si (KR); Jong Bae Yoon, Suwon-si (KR); Ki Seok Park, Siheung-si (KR); and Ho Tae Nam, Suwon-si (KR)
Assigned to SAMJIN PHARMACEUTICAL CO., LTD., Seoul (KR); and ASTECH. CO., LTD., Gyeonggi-Do (KR)
Appl. No. 14/784,956
Filed by SAMJIN PHARMACEUTICAL CO., LTD., Seoul (KR); and ASTECH. CO., LTD., Suwon-si (KR)
PCT Filed Apr. 17, 2014, PCT No. PCT/KR2014/003329
§ 371(c)(1), (2) Date Oct. 16, 2015,
PCT Pub. No. WO2014/171748, PCT Pub. Date Oct. 23, 2014.
Claims priority of application No. 10-2013-0043141 (KR), filed on Apr. 18, 2013.
Prior Publication US 2016/0081922 A1, Mar. 24, 2016
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/5377 (2006.01); A61K 31/4704 (2006.01); A61P 27/00 (2006.01); A61K 31/4725 (2006.01); A61K 9/00 (2006.01); A61K 31/496 (2006.01)
CPC A61K 9/0053 (2013.01) [A61K 31/4704 (2013.01); A61K 31/496 (2013.01); A61K 31/5377 (2013.01)] 11 Claims
 
1. An oral pharmaceutical composition, comprising a pharmaceutically acceptable salt of a prodrug of rebamipide, as an active ingredient,
wherein the prodrug of rebamipide is 2-morpholinoethyl 2-(4-chlorobenzamido)-3-(2-oxo-1,2-dihydroquinolin-4-yl)propanoate represented by Chemical Formulae II, and
wherein the pharmaceutically acceptable salt is a sulfate of a prodrug of rebamipide, a malonate of a prodrug of rebamipide, or an oxalate of a prodrug of rebamipide:

OG Complex Work Unit Chemistry